Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereof
View Patent ↗An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.
1. A pharmaceutical composition comprising (a) an IL-1β binding antibody or IL-1β binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:15, and (b) a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , wherein the antibody or fragment comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:11.
3. The pharmaceutical composition of claim 1 , wherein the antibody or antibody fragment is a Fab, an F(ab′)2, an Fv, or a single-chain antibody fragment.
4. The pharmaceutical composition of claim 1 , wherein the antibody or antibody fragment is a neutralizing antibody.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in a form suitable for intraarticular, subcutaneous, intravenous, intraperitoneal, intracerebral, intraparenchymal, intracerebroventricular, intramuscular, intraocular, intraarterial, intralesional, oral or inhalation administration.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a lyoprotectant, a surfactant, a filler, a binder, and/or bulking agent.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a controlled-release or sustained-release pharmaceutical composition.
8. A pharmaceutical composition comprising (a) an IL-1β binding antibody or IL-1β binding fragment thereof, wherein the antibody or fragment binds to human IL-1β with a dissociation constant less than 1 pM, and the antibody or fragment binds to substantially the same epitope that an antibody having the light chain variable region of SEQ ID NO:11 and the heavy chain variable region of SEQ ID NO:15 binds to, and (b) a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 8 , wherein the antibody or antibody fragment is a Fab, an F(ab′)2, an Fv, or a single-chain antibody fragment.
10. The pharmaceutical composition of any of claim 8 , wherein the antibody or antibody fragment is a neutralizing antibody.
11. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is in a form suitable for intraarticular, subcutaneous, intravenous, intraperitoneal, intracerebral, intraparenchymal, intracerebroventricular, intramuscular, intraocular, intraarterial, intralesional, oral or inhalation administration.
12. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition comprises a lyoprotectant, a surfactant, a filler, a binder, and/or bulking agent.
13. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is a controlled-release or sustained-release pharmaceutical composition.